Pfizer Inc and Johnson & Johnson said they were scrapping further studies of one of the most anticipated experimental Alzheimer's disease treatments after the drug failed to help patients with the memory-robbing condition in a second high-profile late stage clinical trial.
The companies said they would discontinue all other studies of the drug bapineuzumab, including two more late stage trials and follow-up extension studies, in patients with mild to moderate Alzheimer's.
Source: Reuters. Read full article. (link)